Unlabeled Use:
Absorption: Well absorbed but undergoes extensive first-pass hepatic metabolism.
Distribution: Moderate CNS penetration. Crosses the placenta; enters breast milk.
Protein Binding: 93%.
Metabolism/Excretion: Almost completely metabolized by the liver (primarily for CYP2D6 isoenzyme) (the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly ↑ propranolol concentrations and an ↑ risk of adverse effects).
Half-life: 3.46 hr.
Contraindicated in:
Use Cautiously in:
CV: ARRHYTHMIAS, BRADYCARDIA, HF, PULMONARY EDEMA, orthostatic hypotension, peripheral vasoconstriction.
Derm: ERYTHEMA MULTIFORME, EXFOLIATIVE DERMATITIS, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS, itching, rash.
EENT: blurred vision, dry eyes, nasal stuffiness.
Endo: hyperglycemia, hypoglycemia (↑ in children).
GI: constipation, diarrhea, nausea.
GU: erectile dysfunction, ↓ libido.
MS: arthralgia, back pain, muscle cramps, myopathy.
Neuro: paresthesia , fatigue, weakness, anxiety, dizziness, drowsiness, insomnia, memory loss, mental depression, mental status changes, nervousness, nightmares.
Resp: bronchospasm, wheezing.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), drug-induced lupus syndrome.
Drug-Drug:
IV Administration:
Hemangeol, Inderal, Inderal LA, InnoPran XL
Therapeutic Classification: antianginals, antiarrhythmics (Class II), antihypertensives, vascular headache suppressants
Pharmacologic Classification: beta blockers
(Generic available)
(cardiovascular effects)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 30 min | 6090 min | 612 hr |
POER | unknown | 6 hr | 24 hr |
IV | immediate | 1 min | 46 hr |
Following single dose, full effect not seen until several wk of therapy.
NDC Code*